肝炎治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Hepatitis Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月21日 | 出版商:

Global Market Insights Inc. | 英文 231 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球肝炎治疗市场估值达到 222 亿美元，预计在预测期内复合年增长率为 3.5%。该市场的主要动力是乙型肝炎和丙型肝炎感染发病率的上升以及全球对这些疾病的认识不断增强。抗病毒疗法和免疫疗法等治疗方案的创新正在改善患者护理并促进市场扩张。此外，聚合酶链反应（PCR）检测等诊断技术的进步改善了早期检测，进一步刺激了对肝炎治疗的需求。

整个肝炎治疗行业根据疾病类型、治疗类型、给药途径、最终用户和地区进行分类。

市场根据疾病类型、治疗类型、给药途径和最终用户进行细分。在疾病类型中，丙型肝炎细分市场占主导地位，到 2023 年将达到 98 亿美元。製药公司正在大力投资研发，以提高药物疗效、缩短治疗时间并尽量减少副作用。

在治疗类型方面，由于肝炎感染盛行率不断上升，2023年抗病毒药物占了61.4%的主要份额。这些疗法对于治疗肝炎至关重要，特别是对于 B 型和 C 型肝炎，它们可以减少病毒量并控制疾病进展。由于人们对该疾病的认识不断提高以及早期诊断的重要性，新兴市场对抗病毒药物的需求也在增加。

就给药途径而言，由于其便利性和患者依从性高，口服给药预计到 2032 年将达到 121 亿美元。口服疗法，特别是直接作用的抗病毒药物，以更高的疗效和更少的副作用彻底改变了肝炎治疗。

在最终用户类别中，包括医院和专科诊所在内的医疗保健提供者预计将以 3.5% 的复合年增长率成长。这些提供者在实施抗病毒治疗、进行诊断和监测患者病情进展方面发挥关键作用。疫苗接种计划和减少伤害服务等公共卫生措施也促进了这一领域的成长。

从地区来看，在抗病毒疗法的进步和强大的医疗基础设施的推动下，到 2032 年，北美地区的销售额预计将达到 134 亿美元。由于肝炎病例的增加和治疗方案的不断变化，欧洲，尤其是英国，正在经历强劲的成长。在亚太地区，在早期检测、获得负担得起的治疗以及政府主导的肝炎管理计划的支持下，市场预计将以 4.1% 的复合年增长率扩张。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Service Provider
Medication Manufacturers

简介目录

Product Code: 10910

The Global Hepatitis Treatment Market reached a valuation of USD 22.2 billion in 2023 and is expected to grow at a CAGR of 3.5% through the forecast period. The market is primarily driven by the rising incidence of hepatitis B and C infections and the growing global awareness surrounding these conditions. Innovations in treatment options, such as antiviral therapies and immunotherapies, are enhancing patient care and contributing to market expansion. Additionally, advancements in diagnostic technologies like polymerase chain reaction (PCR) testing have improved early detection, further fueling demand for hepatitis treatments.

The overall hepatitis treatment industry is segregated based on Disease Type, Treatment Type, Route of Administration, End-user, and Region.

The market is segmented based on disease type, treatment type, route of administration, and end-user. Among disease types, the hepatitis C segment dominated with USD 9.8 billion in 2023. Rising infection rates and advancements in antiviral treatments are propelling the growth of this segment. Pharmaceutical companies are heavily investing in R&D to enhance drug efficacy, reduce treatment durations, and minimize side effects.

In terms of treatment types, antiviral drugs captured a major share of 61.4% in 2023, driven by the growing prevalence of hepatitis infections. These therapies are crucial in managing hepatitis, particularly for types B and C, where they decrease the viral load and control disease progression. The demand for antiviral drugs is also increasing in emerging markets due to rising awareness of the disease and the importance of early diagnosis.

Regarding the route of administration, the oral segment is set to reach USD 12.1 billion by 2032, thanks to its convenience and high patient compliance. Oral therapeutics, especially direct-acting antivirals, have revolutionized hepatitis treatment with higher efficacy and fewer side effects.

In the end-user category, healthcare providers, including hospitals and specialty clinics, are expected to grow at a CAGR of 3.5%. These providers play a key role in administering antiviral therapies, conducting diagnostics, and monitoring patient progress. Public health initiatives, such as vaccination programs and harm reduction services, also contribute to this segment's growth.

Regionally, North America is projected to reach USD 13.4 billion by 2032, driven by advancements in antiviral therapies and a strong healthcare infrastructure. Europe, particularly the UK, is experiencing robust growth due to rising hepatitis cases and evolving treatment options. In Asia-Pacific, the market is expected to expand at a CAGR of 4.1%, supported by early detection, access to affordable therapies, and government-led hepatitis management programs.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of hepatitis infections
  - 3.2.1.2 Advancements in drug development
  - 3.2.1.3 Rising demand for combination therapies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of medications
  - 3.2.2.2 Side effects and adverse reactions
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Hepatitis A
5.3 Hepatitis B
5.4 Hepatitis C
5.5 Other hepatitis types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Anti-viral drugs
- 6.2.1 Nucleoside/nucleotide analogues
- 6.2.2 Polymerase inhibitors
- 6.2.3 Protease inhibitors
- 6.2.4 Other anti-viral drugs
6.3 Immune modulators (interferons)
6.4 Combination therapies
6.5 Liver transplant
6.6 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By End-user, 2021-2032 ($ Mn)

8.1 Key trends
8.2 Healthcare providers
- 8.2.1 Hospitals
- 8.2.2 Specialty clinics
8.3 Patients
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Service Provider
- 10.1.1 Barnes-Jewish Hospital
- 10.1.2 Bumrungrad International Hospital
- 10.1.3 Cedars-Sinai
- 10.1.4 Cleveland Clinic
- 10.1.5 Mayo Clinic
10.2 Medication Manufacturers
- 10.2.1 AbbVie Inc.
- 10.2.2 Biocon, Inc.
- 10.2.3 Bristol-Myers Squibb Company
- 10.2.4 Dynavax Technologies
- 10.2.5 F. Hoffmann-La Roche Ltd.
- 10.2.6 Gilead Sciences, Inc.
- 10.2.7 GlaxoSmithKline plc
- 10.2.8 Lupin Limited
- 10.2.9 Merck and Co., Inc.
- 10.2.10 Novartis AG